US 12,201,618 B2
Use of riluzole prodrugs to treat Alzheimer's disease
Vladimir Coric, Madison, CT (US); Robert Berman, New Haven, CT (US); and Irfan Qureshi, Hackensack, NJ (US)
Assigned to Biohaven Therapeutics Ltd., Tortola (VG)
Filed by Biohaven Therapeutics Ltd., New Haven, CT (US)
Filed on Jan. 18, 2021, as Appl. No. 17/151,577.
Application 17/151,577 is a continuation in part of application No. 17/261,057, previously published as PCT/US2019/042718, filed on Jul. 20, 2019.
Claims priority of provisional application 62/701,814, filed on Jul. 22, 2018.
Prior Publication US 2021/0212999 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/428 (2006.01); A61K 9/48 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/428 (2013.01) [A61K 9/48 (2013.01); A61P 25/28 (2018.01)] 7 Claims
 
1. A method of treating Alzheimer's Disease of mild to moderate severity in a patient in need thereof, the method comprising administering to the patient a riluzole prodrug having the following formula:

OG Complex Work Unit Chemistry
wherein the riluzole prodrug is administered to the patient at a dosage of 280 mg once per day or a dosage of 140 mg twice per day.